CA2382090A1 - Systeme de vecteur derive de virus coxsackie pour le transfert genique - Google Patents
Systeme de vecteur derive de virus coxsackie pour le transfert genique Download PDFInfo
- Publication number
- CA2382090A1 CA2382090A1 CA002382090A CA2382090A CA2382090A1 CA 2382090 A1 CA2382090 A1 CA 2382090A1 CA 002382090 A CA002382090 A CA 002382090A CA 2382090 A CA2382090 A CA 2382090A CA 2382090 A1 CA2382090 A1 CA 2382090A1
- Authority
- CA
- Canada
- Prior art keywords
- rna molecule
- genome
- dna
- plasmid
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 90
- 239000013598 vector Substances 0.000 title claims abstract description 83
- 241000709687 Coxsackievirus Species 0.000 title claims abstract description 16
- 238000012546 transfer Methods 0.000 title description 18
- 239000013612 plasmid Substances 0.000 claims abstract description 71
- 210000002845 virion Anatomy 0.000 claims abstract description 41
- 208000015181 infectious disease Diseases 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000002458 infectious effect Effects 0.000 claims abstract description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 106
- 210000004027 cell Anatomy 0.000 claims description 83
- 241000700605 Viruses Species 0.000 claims description 53
- 108020004414 DNA Proteins 0.000 claims description 28
- 239000002299 complementary DNA Substances 0.000 claims description 19
- 238000001415 gene therapy Methods 0.000 claims description 13
- 241000701161 unidentified adenovirus Species 0.000 claims description 11
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 9
- 238000001890 transfection Methods 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000001086 cytosolic effect Effects 0.000 claims description 5
- 108090000565 Capsid Proteins Proteins 0.000 claims description 4
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 4
- 108060004795 Methyltransferase Proteins 0.000 claims description 4
- 101800001494 Protease 2A Proteins 0.000 claims description 4
- 101800001491 Protease 3C Proteins 0.000 claims description 4
- 101710172711 Structural protein Proteins 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 241000450599 DNA viruses Species 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 231100001083 no cytotoxicity Toxicity 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 101800001065 Protein 2B Proteins 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 241000709675 Coxsackievirus B3 Species 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000991587 Enterovirus C Species 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 101710081079 Minor spike protein H Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241000897111 recombinant polioviruses Species 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 1
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 1
- 101000742334 Bdellovibrio phage phiMH2K Replication-associated protein VP4 Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 1
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 1
- 101000714465 Chrysanthemum virus B Capsid protein Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 1
- 101000852023 Halorubrum pleomorphic virus 1 Envelope protein Proteins 0.000 description 1
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000030498 cytoplasmic translation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000021 endosomolytic effect Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- MVMXJBMAGBRAHD-UHFFFAOYSA-N picoperine Chemical compound C=1C=CC=NC=1CN(C=1C=CC=CC=1)CCN1CCCCC1 MVMXJBMAGBRAHD-UHFFFAOYSA-N 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32341—Use of virus, viral particle or viral elements as a vector
- C12N2770/32343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne une molécule d'ARN recombiné pouvant être traduite au moins en partie dans une cellule cible. Cette molécule d'ARN présente un génome viral non infectieux du virus Coxsackie du groupe B, de préférence du sérotype B3, et au moins un gène étranger qui provoque une fonction souhaitée, par exemple dans le cadre d'une thérapie génique, dans la cellule cible. Cette molécule d'ARN peut être codée par un plasmide vecteur et/ou être empaquetée sous forme de génome dans un virion permettant d'infecter la cellule cible. L'invention concerne en outre des procédés pour produire la molécule d'ARN, les virions et le plasmide vecteur, ainsi que des kits correspondants.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19939095A DE19939095A1 (de) | 1999-08-18 | 1999-08-18 | Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer |
| DE19939095.9 | 1999-08-18 | ||
| PCT/EP2000/007768 WO2001012815A1 (fr) | 1999-08-18 | 2000-08-10 | Systeme de vecteur derive de virus coxsackie pour le transfert genique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2382090A1 true CA2382090A1 (fr) | 2001-02-22 |
Family
ID=7918752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002382090A Abandoned CA2382090A1 (fr) | 1999-08-18 | 2000-08-10 | Systeme de vecteur derive de virus coxsackie pour le transfert genique |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1210439A1 (fr) |
| JP (1) | JP2003507014A (fr) |
| AU (1) | AU6281600A (fr) |
| CA (1) | CA2382090A1 (fr) |
| DE (1) | DE19939095A1 (fr) |
| WO (1) | WO2001012815A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107760719A (zh) * | 2017-10-24 | 2018-03-06 | 胜武（北京）生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
| US10041087B2 (en) | 2012-06-19 | 2018-08-07 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10087460B2 (en) | 2013-08-12 | 2018-10-02 | BASF Agro B.V. | Transgenic or non-transgenic plants with mutated protoporphyrinogen oxidase having increased tolerance to herbicides |
| US10100329B2 (en) | 2012-06-19 | 2018-10-16 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10392630B2 (en) | 2013-08-12 | 2019-08-27 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US11274313B2 (en) | 2010-12-16 | 2022-03-15 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| WO2023077484A1 (fr) * | 2021-11-06 | 2023-05-11 | 江汉大学 | Combinaison de marqueurs mnp de cinq entérovirus humains, combinaison de paires d'amorces, kit et utilisations associées |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US606385A (en) * | 1898-06-28 | Thirds to george h | ||
| US6071742A (en) * | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
-
1999
- 1999-08-18 DE DE19939095A patent/DE19939095A1/de not_active Withdrawn
-
2000
- 2000-08-10 AU AU62816/00A patent/AU6281600A/en not_active Abandoned
- 2000-08-10 WO PCT/EP2000/007768 patent/WO2001012815A1/fr not_active Ceased
- 2000-08-10 JP JP2001516902A patent/JP2003507014A/ja active Pending
- 2000-08-10 CA CA002382090A patent/CA2382090A1/fr not_active Abandoned
- 2000-08-10 EP EP00949478A patent/EP1210439A1/fr not_active Withdrawn
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274313B2 (en) | 2010-12-16 | 2022-03-15 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US12570994B2 (en) | 2010-12-16 | 2026-03-10 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US11441154B2 (en) | 2012-06-19 | 2022-09-13 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10100329B2 (en) | 2012-06-19 | 2018-10-16 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US11572571B2 (en) | 2012-06-19 | 2023-02-07 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US12529066B2 (en) | 2012-06-19 | 2026-01-20 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10041087B2 (en) | 2012-06-19 | 2018-08-07 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10392630B2 (en) | 2013-08-12 | 2019-08-27 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10968462B2 (en) | 2013-08-12 | 2021-04-06 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US10982227B2 (en) | 2013-08-12 | 2021-04-20 | BASF Agro B.V. | Transgenic or non-transgenic plants with mutated protoporphyrinogen oxidase having increased tolerance to herbicides |
| US10087460B2 (en) | 2013-08-12 | 2018-10-02 | BASF Agro B.V. | Transgenic or non-transgenic plants with mutated protoporphyrinogen oxidase having increased tolerance to herbicides |
| US11827896B2 (en) | 2013-08-12 | 2023-11-28 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
| US11866720B2 (en) | 2013-08-12 | 2024-01-09 | BASF Agro B.V. | Transgenic or non-transgenic plants with mutated protoporphyrinogen oxidase having increased tolerance to herbicides |
| CN107760719B (zh) * | 2017-10-24 | 2020-09-22 | 北京领柯生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
| CN107760719A (zh) * | 2017-10-24 | 2018-03-06 | 胜武（北京）生物科技有限公司 | 柯萨奇病毒在过继免疫基因递送系统中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19939095A1 (de) | 2001-02-22 |
| WO2001012815A1 (fr) | 2001-02-22 |
| JP2003507014A (ja) | 2003-02-25 |
| EP1210439A1 (fr) | 2002-06-05 |
| AU6281600A (en) | 2001-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Howarth et al. | Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells) | |
| JP4018479B2 (ja) | Ｄｎａ発現系 | |
| JP4686670B2 (ja) | 組換えウイルスの製造方法 | |
| US7572453B2 (en) | Chimeric alphavirus replicon particles | |
| Hu et al. | Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells | |
| EP1035209A1 (fr) | Virus influenza recombinants stables dépourvus de virus auxiliaire | |
| Porter et al. | Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans | |
| JPH11506318A (ja) | 組換えウイルスベクター系 | |
| Kohno et al. | Semliki Forest virus-based DNA expression vector: transient protein production followed by cell death | |
| JP2022523719A (ja) | Ａａｖキャプシドの転写依存性定方向進化を使用するための方法 | |
| WO2002042434A1 (fr) | Cellules destinees a etre utilisees pour produire un vecteur de virus, procede pour les produire et processus pour produire un vecteur de virus en utilisant ces cellules | |
| CA2382090A1 (fr) | Systeme de vecteur derive de virus coxsackie pour le transfert genique | |
| US7208315B2 (en) | Compositions and methods for efficient AAV vector production | |
| AU2021374174A9 (en) | Production of virus vector plasmid in bacillus subtilis | |
| Lu et al. | Construction and genetic analysis of dicistronic polioviruses containing open reading frames for epitopes of human immunodeficiency virus type 1 gp120 | |
| JP6747983B2 (ja) | 感染性ｒｎａウイルスを迅速に生成するための方法 | |
| JP2006501841A (ja) | 日本脳炎ウイルスの全長のゲノムＲＮＡ及び該ＪＥＶゲノムＲＮＡに対する感染性を有するＪＥＶｃＤＮＡ及びその用途 | |
| Ponder | Vectors in gene therapy | |
| RU2398875C2 (ru) | Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы | |
| Liu et al. | The genomic 5′ terminus of Manchester calicivirus | |
| Cheng et al. | A cDNA-based reverse genetics system for feline calicivirus identifies the 3′ untranslated region as an essential element for viral replication | |
| Eiz et al. | Immunological adenovirus variant strains of subgenus D: comparison of the hexon and fiber sequences | |
| CN1478147A (zh) | 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法 | |
| Meyer et al. | Plasmid-based generation of recombinant coxsackievirus B3 particles carrying capsid gene replacement replicons | |
| Zhu et al. | Selection and characterization of packaging cell lines for XJ-160 virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |